Comparison of urinary MNP22™ and BTA-stat™ with voided urinary cytology and cystoscopy in the detection and follow-up of bladder cancer: Can urinary NMP22™ and BTA-stat™-test replace cystoscopy?;Vergleich des NMP22™-und BTA-stat™-tests mit der urinzytologie und zystoskopie in der diagnose und nachsorge des blasenkarzinoms: Können die NMP22™-und BTA-stat™-tests die zystoskopie ersetzen?

Aktuelle Urologie

Volumn 30, Issue 7, 1999, Pages 466-475

  Poulakis, Vassilis ^a,b   Witzsch, U ^a   Kollias, A ^a   Wolfram, M ^a   Becht, E ^a,c   Altmannsberger, H M ^a  

^a GOETHE UNIVERSITY   (Germany)

^b Krankenhaus Nordwest ^*  (Germany)

^c KRANKENHAUS NORDWEST   (Germany)

Author keywords

Bladder cancer; BTA stat test; Cystoscopy; NMP22 test; Urine cytology

Indexed keywords

EID: 0004520784     PISSN: 00017868     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0029-1202671     Document Type: Article

References (41)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin 1998; 48: 6-29
2. th Edition. Band II. Philadelphia: WB Saunders, 1992. 1094-1158
3. Abel PD. Prognostic Indices in transitional cell carcinoma of the bladder. Br J Urol 1988; 62: 103-109
4. Lutzeyer W, Ruebben H, Dahm H. Prognostic Parameters in superficial bladder cancer: an analysis of 315 cases. J Urol 1982; 127: 250-252
5. Deutsche Gesellschaft für Urologie. Leitlinien zur Diagnostik und Therapie des Harnblasenkarzinoms. Urologe [A] 1998; 37: 440-457
6. Murphy WM. Current status of urinary cytology in the evaluation of bladder neoplasms. Hum Path 1990; 21: 886-896
7. Sarosdy MF, de Vere White RW, Soloway MS, Sheinfeld J, Hudson MA, Schellhammer PF, Jarowenko MV, Adams G, Blumenstein BA. Results of a multicenter trial using the BTA Test to monitor for and diagnose recurrent bladder cancer. J Urol 1995; 154: 379-384
8. Soloway MS, Briggman V, Carpinito GA, Chodak GW, Church PA, Lamm KL, Lange P, Messing E, Pasciak RM, Reservitz GB, Rustalis DB, Sarosdy MF, Stadler WM, Thiel RP, Hayden CL. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol 1996; 156: 363-367
9. Schmetter BS, Habicht KK, Lamm DL, Morales A, Bander NH, Grossman HB, Hanna MG, Silberman SR, Butman BT. A multicenter trial evaluation of the fibrin/fibrinogen degradation products test for detection and monitoring of bladder cancer. J Urol 1997; 158: 801-805
10. Sarosdy MF. Editorial: Data interpretation and integration of new tests into clinical practice. J Urol 1997; 158: 2107-2108
11. Stampfer DS, Carpinito GA, Rodriguez-Villanueva J, Willsey LW, Dinney CP, Grossman HB, Fritsche HA, McDougal WS. Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. J Urol 1998; 158: 394-398
12. Bard®-BTA® Test Kit, Bard Diagnostic Sciences, Inc. Redmond, WA 98052 USA. Test Instruction. Issued 4/96
13. Conn IG, Crocker J, Wallace DMA, Hughes MA, Hilton CJ. Basement membranes in urothelial carcinoma. Brit J Urol 1987; 60: 536-542
14. Kinders R, Jones T, Root R, Murchison H, Bruce C, Williams L, Hass GM. Human bladder tumor antigen is a membran of the RCA (regulators of complement activation) gene family. J Urol 1997; 157 (suppl): 28
15. Berezney R. The nuclear matrix: a heuristic model for investigating genomic organization and function in the cell nucleus. J Cell Biochem 1991; 47: 109-123
16. Getzenberg RH, Konety BR, Oeler TA, Quigley MM, Hakam A, Becich MJ, Bahnson RR. Bladder cancer-associated nuclear matrix proteins. Cancer Res 1996; 56: 1690-1694
17. rd Edition. Oxford: Blackwell, 1994. 403-407
18. Huland H, Arndt R, Huland E, Loening T, Steffens M. Monoclonal antibody 486 P 3/12: a valuable bladder carcinoma marker for immuncytology. J Urol 1987; 137: 654-659
19. Yoshida K, Sugino T, Tahara H, Woodman A, Bolodeoku J, Nargund V, Fellows G, Goodison S, Tahara E, Tarin D. Telomerase activity in bladder carcinoma and its implication for noninvasive diagnosis by detection of exfoliated cancer cells in urine. Cancer 1997; 79: 362-369
20. Mao L, Schoenberg MP, Scicchitano M, Erosan YS, Merlo A, Schwab D, Sindransky D. Molecular detection of primary bladder cancer by microsatellite analysis. Science 1996; 271: 659-662
21. Wawroschek F, Rathert P. Urinzytologie. Urologe [A] 1995; 34: 69-75
22. Pariente JL, Bordenave L, Michel Ph, Latapie MJ, Ducassou D, Guillou MLE. Initial evaluation of CYFRA 21-1. Diagnostic performances as a urinary marker in bladder transitional cell carcinoma. J Urol 1997; 158: 338-341
23. Oosterlink W, Kurth K-H, Schröder F, Bultinck J, Hammond B, Sylvester R and member of the European Organization for Research on Treatment of Cancer. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 1993; 149: 749-752
24. Johnston B, Morales A, Emerson L, Lundie M. Rapid detection of bladder cancer: a comparative study of point of care tests. J Urol 1997; 158: 2098-2101
25. Wawroschek F, Stockhausen D, Rathert P. Standardurinzytologie vs. Teststreifendiagnostik. Eine vergleichende prospektive Untersuchung zur Sensitivität und Spezifität in der Detektion urothelialer Karzinome. Urologe [B] 1996; 36: 283-286
26. Leyh H, Hall R, Mazeman E. Wertigkeit von BTA-Test und Urinzytologie bei der Diagnostik und Nachsorge des Harnblasenkarzinoms. Akt Urol 1998; 29: 57-61
27. The United Kingdom and Eire Bladder Tumor Antigen Study Group. The use of the bladder-tumour associated analyse test to determine the type of cystoscopy in the follow-up of patients with bladder cancer. Br J Urol 1997; 79: 362-366
28. Sarosdy MF, Hudson MA, Ellis WJ, Soloway MS, White RdeV, Sheifeld J, Jarowenko MV, Schellhammer PF, Schervish EW, Patel JV, Chodak GW, Lamm DL, Johnson RD, Henderson M, Adams G, Blumenstein BA, Thoelke KR, Pfalzgraf RD, Murichson HA, Brunell SL. Improved detection of recurrent bladder cancer using the Bard BTA stat test. Urology 1997; 50: 349-353
29. Wiener H, Mian CH, Haitel A, Pycha A, Schatzl G, Marberger M. Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer? J Urol 1998; 159: 1876-1880
30. Leyh H, Marberger M, Conort P, Sternberg C, Pansadoro V, Pagano F, Bassi P, Boccon-Gibod L, Ravery V, Treiber U, Ishak L. Comparison of the BTAstat™ Test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer. Eur Urol 1999; 35: 52-56
31. Zein TA, Milad MF. Urine cytology in bladder tumours. Int Surg 1991; 76: 52-54
32. Leyh H, Mazeman E. Bard BTA test compared with voided cytology in the diagnosis of recurrent bladder cancer. Eur Urol 1997; 32; 425-428
33. Ramakumar S, Bhuiyan J, Besse JA, Roberts SG, Wollan PC, Blute ML, O'Kane DJ. Comparison of screening methods in the detection of bladder cancer. J Urol 1999; 161: 388-394
34. Pode V, Shapiro A, Wald M, Nativ O, Laufer M, Kaver I. Noninvasive detection of bladder with the BTAstat Test. J Urol 1999; 161: 443-446
35. Carpinito GA, Stadler WM, Briggmann JV, Briggman JV, Chodak GW, Church PA, Lamm DL, Lange PH, Messing EM, Pasciak RM, Reservitz GB, Ross RN, Rustaklis DB, Sarosdy MF, Soloway MS, Thiel RP, Vogelzang NJ, Hayden CL. Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract. J Urol 1996; 156: 1280-1285
36. Witjes JA, van der Poel HG, van Balken MRet al. Urinary NMP22 and karyometry in the diagnosis and follow-up of patients with superficial bladder cancer. Eur Urol 1998; 33: 387-391
37. Heney NM, Ahmed S, Flanagan MJ, Frable W, Corder MP, Hafermann MD, Hawkins IR. Superficial bladder cancer: progression and recurrence. J Urol 1983; 130: 1083-1086
38. Van der Poel HG, Van Balken MR, Schamhart DH, Peelen P, de Reijke Th, Debruyne FMJ, Schalken JA, Witjes JA. Bladder wash cytology, quantitative cytology, and the qualitative BTA test in patients with superficial bladder cancer. Urology 1998; 51: 44-50
39. Irani J, Desgrandchamps F, Millet C, Toubert M-E, Bon D, Aubert J, Le Duc A. BTAstat and BTA TRAK: a comparative evaluation of urine testing for the diagnosis of transitional cell carcinoma of the bladder. Eur Urol 1999; 35: 89-92
40. Droller MJ. Improved detection of recurrent bladder cancer using the Bard BTA stat Test. J Urol 1998; 159: 601-602
41. Soloway MS. Editorial: Do we have a prostate specific antigen for bladder cancer. J Urol 1999; 161: 447-448